Nutrilipid I.v. Fat Emulsion

For adult patients, the dosage of Soybean Oil is individualized based on the patient's caloric requirements, body weight, and ability to metabolize lipids.

• Standard Caloric Support: The typical dose ranges from 1 g/kg/day to 2 g/kg/day.
• Maximum Dose: It is generally recommended not to exceed 2.5 g/kg/day or 60% of the patient's total daily caloric intake.
• Infusion Rate: To minimize the risk of adverse effects, the infusion should begin slowly, often at 0.5 mL/minute to 1.0 mL/minute for the first 15 to 30 minutes. If tolerated, the rate can be increased. The total daily dose should ideally be infused over 12 to 24 hours.

In pediatric patients, particularly neonates, Soybean Oil is vital for growth but must be administered with extreme caution.

• Neonates and Infants: Dosing usually starts low at 0.5 g/kg/day to 1 g/kg/day and is gradually increased by 0.5 g/kg increments based on plasma triglyceride monitoring.
• Maximum Pediatric Dose: Up to 3 g/kg/day may be used in infants, provided they demonstrate adequate lipid clearance.
• Premature Infants: These patients are at a higher risk of hyperlipidemia and require very slow infusion rates (often over 24 hours) to prevent fat accumulation in the lungs.

Renal Impairment

While Soybean Oil itself is not primarily cleared by the kidneys, patients with renal impairment often have altered lipid metabolism. Close monitoring of serum triglycerides is essential. In patients with acute kidney injury, fluid restriction may require the use of more concentrated (20% or 30%) emulsions to limit volume intake.

Hepatic Impairment

Patients with pre-existing liver disease or Parenteral Nutrition-Associated Liver Disease (PNALD) require careful dosage titration. Excessive lipid administration can exacerbate cholestasis (reduced bile flow). Healthcare providers may reduce the dose or frequency (e.g., 'lipid-free' days) to allow the liver to clear accumulated lipids.

Elderly Patients

Geriatric patients often have a reduced capacity to clear fat emulsions. Dosing should start at the lower end of the range, and monitoring for hypertriglyceridemia should be more frequent, especially if the patient has underlying cardiovascular disease or diabetes.

Soybean Oil is administered exclusively via intravenous infusion. It can be administered through a peripheral vein (usually the 10% or 20% formulations) or a central venous catheter.

• Aseptic Technique: Because lipid emulsions support rapid bacterial growth, strict sterile technique is mandatory during setup.
• Filters: A 1.2-micron in-line filter is required during administration to remove any large lipid globules or precipitates that could cause an embolism (blood vessel blockage).
• Admixtures: Soybean Oil is often mixed with amino acids and dextrose in a single bag (Total Nutrient Admixture or '3-in-1'). These must be inspected for 'creaming' or 'oiling out' (separation of the emulsion), which indicates the mixture is unsafe to use.
• Storage: Store at controlled room temperature (25°C/77°F). Do not freeze, as freezing destroys the emulsion stability.

In a hospital setting, missed doses are rare as infusions are managed by automated pumps. If an infusion is interrupted, it should be restarted as soon as possible at the prescribed rate. Do not double the infusion rate to 'catch up,' as this significantly increases the risk of Fat Overload Syndrome.

An overdose of Soybean Oil occurs when the rate of infusion exceeds the body's ability to clear the lipids. Signs of acute overdose include:

• Sudden fever and chills
• Respiratory distress (difficulty breathing)
• Cyanosis (bluish skin color)
• Severe nausea and vomiting

In the event of a suspected overdose, the infusion must be stopped immediately. Emergency measures include respiratory support and monitoring of coagulation and liver function. Severe cases may require plasmapheresis to mechanically remove the excess lipids from the blood.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to manage the infusion equipment without medical guidance.

Patients receiving Soybean Oil infusions may experience mild systemic reactions, particularly during the initial phase of treatment. These include:

• Fever and Chills: Often referred to as a 'pyrogenic reaction,' this typically occurs if the infusion rate is too rapid.
• Nausea and Vomiting: General gastrointestinal upset as the body adjusts to the high lipid load.
• Headache: A common transient symptom during the first few days of therapy.
• Increased Triglycerides: A temporary rise in blood fats is expected, but levels must be monitored to ensure they stay within a safe range (usually <200-400 mg/dL).

• Dizziness and Flushing: A feeling of warmth or redness in the face and neck.
• Diaphoresis: Excessive sweating.
• Sleepiness: Some patients report mild lethargy during the infusion.
• Injection Site Reactions: Pain, redness, or swelling at the site of the peripheral IV line (thrombophlebitis).

• Fat Overload Syndrome: A rare but life-threatening complication where the body cannot clear the lipids. Symptoms include sudden hepatomegaly (enlarged liver), splenomegaly (enlarged spleen), anemia, leukopenia (low white blood cells), and thrombocytopenia (low platelets).
• Pancreatitis: Inflammation of the pancreas caused by severely elevated triglycerides.
• Hypercoagulability: An increased tendency for the blood to clot.
• Allergic Reactions: Rashes or hives, often related to the egg phospholipid component.

> Warning: Stop the infusion and call your doctor or nurse immediately if you experience any of these symptoms:

• Anaphylaxis: Signs include swelling of the face, lips, or tongue; difficulty swallowing; or severe wheezing. This is a medical emergency.
• Severe Respiratory Distress: Shortness of breath or a feeling of 'tightness' in the chest, which may indicate fat particles have reached the lungs (pulmonary fat embolism).
• Jaundice: Yellowing of the eyes or skin, which may indicate acute liver dysfunction or cholestasis.
• Confusion or Altered Mental Status: This could be a sign of hyperammonemia or severe metabolic imbalance.
• Seizures: Though extremely rare, metabolic shifts can trigger neurological events.

With prolonged use (weeks to months), Soybean Oil can lead to:

• Parenteral Nutrition-Associated Liver Disease (PNALD): This encompasses a spectrum of liver injuries, including steatosis (fatty liver), cholestasis, and eventually cirrhosis or liver failure. It is thought to be caused by the high phytosterol content in soybean oil and the high omega-6 to omega-3 ratio.
• Essential Fatty Acid Imbalance: While it prevents deficiency, the high omega-6 content may promote a pro-inflammatory state in some patients.
• Aluminum Toxicity: Long-term use of parenteral products can lead to aluminum accumulation in the bones and brain, particularly in patients with kidney impairment.

Death in Preterm Infants: The FDA has issued warnings regarding deaths in preterm infants following the infusion of intravenous fat emulsions. Autopsy findings in these cases showed intravascular fat accumulation in the lungs. Preterm and small-for-gestational-age infants have poor clearance of intravenous fat emulsions and increased free fatty acid plasma levels following fat emulsion infusion. Strict adherence to slow infusion rates and constant monitoring of triglyceride levels is mandatory in this population.

Report any unusual symptoms to your healthcare provider. Monitoring is the key to preventing long-term complications.

Soybean Oil is a high-alert medication that requires careful clinical oversight. It is not suitable for all patients, particularly those with certain metabolic disorders or severe allergies. Patients must be screened for egg and soy allergies prior to administration, as the emulsifiers used in these products are derived from egg yolks.

Warning: Risk of Death in Preterm Infants.

As detailed in the side effects section, the FDA requires a warning regarding the risk of pulmonary fat accumulation in premature infants. This risk is highest when the infusion rate is too fast or the infant's metabolic capacity is overwhelmed. Healthcare providers must monitor these patients with extreme vigilance, checking triglyceride levels daily or even more frequently during the initial titration phase.

• Infection Risk (Sepsis): Lipid emulsions are an excellent growth medium for bacteria and fungi (such as Candida albicans). Because the emulsion is administered directly into the bloodstream, any contamination can lead to rapid-onset sepsis. Infusion sets must be changed every 12 hours for pure lipids or 24 hours for 3-in-1 admixtures.
• Hepatotoxicity and Cholestasis: Long-term use can cause liver damage. If liver function tests (ALT, AST, Bilirubin) become significantly elevated, the dose may need to be reduced or discontinued.
• Hyperlipidemia: Patients with pre-existing high cholesterol or triglycerides must be monitored closely. If triglycerides exceed 400 mg/dL in adults or 200 mg/dL in neonates, the infusion should typically be held or reduced.
• Fluid Overload: Patients with congestive heart failure or pulmonary edema must be monitored for fluid shifts, as the volume of the infusion can worsen these conditions.

To ensure safety, the following laboratory tests are typically required:

• Serum Triglycerides: Baseline and then daily until stable, then weekly.
• Liver Function Tests (LFTs): Weekly monitoring of AST, ALT, alkaline phosphatase, and bilirubin.
• Blood Glucose: Lipids can affect insulin sensitivity; monitoring for hyperglycemia is necessary.
• Electrolytes and Renal Function: To ensure the overall TPN formula is balanced.
• Complete Blood Count (CBC): To monitor for signs of infection or the 'Fat Overload Syndrome' (low platelets/WBCs).

Soybean Oil itself does not typically cause impairment that would prevent driving. However, the underlying conditions requiring parenteral nutrition (such as severe illness or recovery from major surgery) usually mean the patient should not operate heavy machinery until cleared by their doctor.

Alcohol should be avoided while receiving Soybean Oil therapy. Alcohol can increase triglyceride levels and put additional strain on the liver, compounding the risks of PNALD and pancreatitis associated with lipid infusions.

Soybean Oil does not require a 'taper' in the traditional sense like steroids. However, when transitioning to oral or enteral feeds, the IV lipid dose is gradually reduced as the patient demonstrates they can absorb enough fat and calories through their digestive tract. Sudden discontinuation is usually only done in cases of severe allergic reaction or fat overload.

> Important: Discuss all your medical conditions, especially any history of liver disease, kidney disease, or blood disorders, with your healthcare provider before starting Soybean Oil.

There are no specific drugs that are absolutely contraindicated with Soybean Oil in terms of systemic pharmacological interaction; however, physical incompatibility is a major concern.

• Incompatible IV Medications: Many drugs will 'break' the emulsion if mixed in the same line. For example, medications with a very low pH (acidic) or those containing high concentrations of divalent cations (like Calcium or Magnesium) can cause the lipid droplets to coalesce into large globules. These globules can cause a fat embolism (blockage of blood flow), which is potentially fatal.

• Warfarin (Coumadin): Soybean Oil naturally contains Vitamin K1 (Phylloquinone). While the amount varies by brand, it is typically around 15 to 25 micrograms per 100 mL. Since Vitamin K is the antidote to Warfarin, starting or stopping Soybean Oil infusions can cause significant fluctuations in a patient's INR (International Normalized Ratio), potentially leading to blood clots or excessive bleeding. Patients on Warfarin require daily INR monitoring when lipid therapy is initiated or changed.
• Corticosteroids: Drugs like prednisone or dexamethasone can increase blood sugar and lipid levels. When used with Soybean Oil, the risk of severe hypertriglyceridemia and hyperglycemia is increased.

• Loop Diuretics (e.g., Furosemide): These can cause dehydration and concentrate the lipids in the blood, potentially increasing the risk of hyperlipidemia.
• Propofol: Propofol is itself formulated in a 10% soybean oil emulsion. If a patient is receiving both TPN with Soybean Oil and sedation with Propofol, the total lipid load can easily exceed the body's clearance capacity, leading to rapid-onset hypertriglyceridemia.

Since Soybean Oil is administered intravenously, traditional food-drug interactions in the stomach do not occur. However, the patient's overall nutritional status is critical.

• High-Carbohydrate Intake: If a patient is receiving very high doses of IV dextrose (sugar) alongside Soybean Oil, the body may prioritize glucose metabolism, leading to slower clearance of the lipids and a higher risk of fatty liver.

• Omega-3 Supplements (Fish Oil): Patients taking oral fish oil supplements while receiving IV Soybean Oil may have altered inflammatory profiles. While not dangerous, the clinical team should be aware to balance the total fatty acid intake.
• St. John's Wort: While primarily a CYP3A4 inducer, its effects on the metabolic stress of the liver should be considered in patients on long-term TPN.

Soybean Oil can interfere with several common laboratory tests if the blood sample is taken while the lipids are still clearing from the blood (lipemic samples):

• Bilirubin: Can be falsely elevated.
• Hemoglobin: May be inaccurately measured due to the cloudiness of the plasma.
• Blood Typing and Cross-matching: High lipid levels can interfere with the visualization of agglutination.
• Strategy: Blood for lab tests should ideally be drawn 4 to 6 hours after the lipid infusion has been stopped, or from a different IV site if the infusion is continuous.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any blood thinners like Warfarin.

Soybean Oil must NEVER be used in the following situations:

1. 1Severe Egg or Soy Allergy: The emulsion uses egg phospholipids as an emulsifier. Patients with a history of anaphylaxis to eggs or soy products are at extreme risk of a fatal reaction.
2. 2Severe Hyperlipidemia: Patients with baseline triglyceride levels over 1000 mg/dL or those with genetic lipid metabolism disorders (such as Type I hyperlipoproteinemia) cannot clear the oil, leading to immediate pancreatitis or embolism.
3. 3Acute Shock: In the initial 'ebb' phase of severe shock, the body's metabolic pathways are shut down, and the infusion of lipids can worsen hemodynamic instability.
4. 4Severe Coagulation Disorders: In the acute phase of disseminated intravascular coagulation (DIC), lipids may interfere with clotting factor function.

Conditions requiring careful risk-benefit analysis include:

• Acute Pancreatitis: If the pancreatitis is caused by high triglycerides, Soybean Oil is contraindicated. If it is caused by gallstones, it may be used with extreme caution.
• Severe Liver Disease: Because the liver is responsible for processing the byproducts of lipid metabolism, patients with end-stage liver disease may not tolerate Soybean Oil.
• Pulmonary Disease: Patients with ARDS (Acute Respiratory Distress Syndrome) or severe pneumonia may have difficulty if lipid particles accumulate in the pulmonary capillaries.
• Anemia or Low Platelets: Because Fat Overload Syndrome can worsen these conditions, patients with pre-existing hematological issues require more frequent monitoring.

Patients who are sensitive to Legumes (peanuts, lentils, beans) may occasionally show cross-reactivity to Soybean Oil, though this is clinically rare compared to the direct soy allergy. Additionally, patients with a known sensitivity to Glycerin should be evaluated, as it is a common component of the emulsion base.

> Important: Your healthcare provider will evaluate your complete medical history, including all known allergies and metabolic conditions, before prescribing Soybean Oil.

Soybean Oil is generally classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. However, essential fatty acids are crucial for fetal brain and retinal development.

• Clinical Use: If a pregnant woman requires parenteral nutrition due to severe hyperemesis gravidarum or malabsorption, Soybean Oil is often used because the risk of maternal and fetal malnutrition far outweighs the theoretical risks of the lipid emulsion.
• Monitoring: Close monitoring of maternal triglyceride levels is required, as pregnancy itself naturally increases lipid levels.

It is not known whether the components of Soybean Oil emulsion are excreted in human milk in amounts that would affect a nursing infant. However, since the components (soybean oil, egg phospholipids) are standard dietary fats, the risk is considered low. The primary consideration is the health of the mother; if she requires TPN, breastfeeding may be metabolically taxing, and a healthcare provider should be consulted regarding the safety of continued lactation.

Soybean Oil is a cornerstone of neonatal intensive care but carries significant risks.

• Approved Age: It is used from birth (including extreme preterm infants) through adolescence.
• Growth Effects: It is essential for weight gain and 'catch-up' growth in sick infants.
• Special Risks: Neonates have a lower concentration of lipoprotein lipase, making them highly susceptible to hyperlipidemia. There is also a risk of kernicterus (brain damage from high bilirubin), as free fatty acids can displace bilirubin from albumin. Bilirubin levels must be monitored closely in jaundiced infants receiving lipids.

Elderly patients (over 65) are more likely to have underlying conditions that complicate lipid therapy, such as:

• Reduced Clearance: Age-related decline in enzyme activity can lead to slower lipid processing.
• Polypharmacy: Increased risk of interactions with medications like Warfarin or diuretics.
• Cardiovascular Stress: The volume and lipid load may be harder on a heart with pre-existing failure or coronary artery disease. Dosing should be conservative.

In patients with chronic kidney disease (CKD) or acute kidney injury (AKI):

• Dose Adjustment: No specific GFR-based formula exists, but the 'lipid load' should be monitored via triglyceride levels.
• Dialysis: Soybean Oil is not cleared by hemodialysis or peritoneal dialysis because the lipid particles are too large to pass through the dialysis membrane. However, the fluid volume of the infusion must be accounted for in the patient's daily fluid balance.

In patients with Child-Pugh Class B or C cirrhosis:

• Risk of Accumulation: The liver's ability to clear lipid byproducts is reduced.
• Monitoring: Frequent LFTs and triglyceride checks are mandatory. If the patient develops signs of worsening cholestasis, the use of 'alternative' lipids (like those containing fish oil or olive oil) may be considered by the specialist team.

> Important: Special populations require individualized medical assessment and frequent laboratory monitoring to ensure the safety of intravenous lipid therapy.

Soybean Oil acts as a biological energy substrate and a source of essential fatty acids. The primary molecular mechanism involves the provision of triglycerides, which are hydrolyzed by lipoprotein lipase (LPL) into free fatty acids (FFAs) and glycerol.

• Energy Production: FFAs enter cells and undergo beta-oxidation in the mitochondria, yielding approximately 9 kilocalories per gram of fat.
• Structural Integrity: Linoleic and alpha-linolenic acids are incorporated into the phospholipid bilayer of cell membranes, ensuring proper fluidity and function of membrane-bound receptors and ion channels.
• Signaling: These fatty acids serve as precursors for the synthesis of bioactive eicosanoids (prostaglandins and leukotrienes) via the cyclooxygenase (COX) and lipoxygenase (LOX) pathways.

• Dose-Response: There is a linear relationship between the infusion rate and the plasma triglyceride concentration, up to the point of metabolic saturation.
• Onset of Effect: Caloric support begins immediately upon starting the infusion. Reversal of essential fatty acid deficiency symptoms (like skin rash) typically takes 1 to 2 weeks of consistent therapy.
• Duration: The metabolic effects last as long as the infusion is maintained. Once stopped, plasma lipid levels typically return to baseline within 4 to 12 hours in patients with normal metabolism.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | >99% (carried by lipoproteins/albumin) |

| Half-life | 30 - 60 minutes (initial clearance) |

| Tmax | End of infusion |

| Metabolism | Lipoprotein Lipase (Endothelial) |

| Excretion | CO2 (Lungs), Glycerol (Renal) |

• Molecular Formula: Predominantly C54H98O6 (as Triolein/Trilinolein equivalents)
• Molecular Weight: Varies (approx. 880 g/mol for typical triglycerides)
• Solubility: Insoluble in water; formulated as an oil-in-water emulsion with egg phospholipids.
• Structure: A mixture of neutral triglycerides of predominantly unsaturated fatty acids (Linoleic 50-55%, Oleic 19-30%, Palmitic 7-12%, Alpha-linolenic 5-10%).

Soybean Oil is classified as a Lipid Emulsion [EPC]. It is often grouped with other parenteral nutrients like Amino Acids and Dextrose. Related medications include newer generation 'mixed' emulsions that combine soybean oil with medium-chain triglycerides (MCT), olive oil, or fish oil (e.g., SMOFlipid).